CA2106693A1 - Immunoassay for isothiazolones - Google Patents
Immunoassay for isothiazolonesInfo
- Publication number
- CA2106693A1 CA2106693A1 CA002106693A CA2106693A CA2106693A1 CA 2106693 A1 CA2106693 A1 CA 2106693A1 CA 002106693 A CA002106693 A CA 002106693A CA 2106693 A CA2106693 A CA 2106693A CA 2106693 A1 CA2106693 A1 CA 2106693A1
- Authority
- CA
- Canada
- Prior art keywords
- isothiazolones
- antibodies
- antibody
- isothiazolone
- hybridoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- JLHMJWHSBYZWJJ-UHFFFAOYSA-N 1,2-thiazole 1-oxide Chemical class O=S1C=CC=N1 JLHMJWHSBYZWJJ-UHFFFAOYSA-N 0.000 title claims abstract description 89
- 238000003018 immunoassay Methods 0.000 title claims abstract description 16
- 210000004408 hybridoma Anatomy 0.000 claims abstract description 64
- 238000000034 method Methods 0.000 claims abstract description 53
- 239000000203 mixture Substances 0.000 claims abstract description 34
- DHNRXBZYEKSXIM-UHFFFAOYSA-N chloromethylisothiazolinone Chemical compound CN1SC(Cl)=CC1=O DHNRXBZYEKSXIM-UHFFFAOYSA-N 0.000 claims abstract description 17
- 230000002163 immunogen Effects 0.000 claims abstract description 14
- 229920002521 macromolecule Polymers 0.000 claims abstract description 14
- 210000004027 cell Anatomy 0.000 claims description 71
- 241001465754 Metazoa Species 0.000 claims description 24
- 239000000126 substance Substances 0.000 claims description 19
- 210000000628 antibody-producing cell Anatomy 0.000 claims description 16
- 210000004881 tumor cell Anatomy 0.000 claims description 14
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 claims description 10
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 claims description 10
- 239000011159 matrix material Substances 0.000 claims description 10
- 239000003153 chemical reaction reagent Substances 0.000 claims description 8
- 210000002966 serum Anatomy 0.000 claims description 8
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 7
- 208000007452 Plasmacytoma Diseases 0.000 claims description 7
- 210000004369 blood Anatomy 0.000 claims description 7
- 239000008280 blood Substances 0.000 claims description 7
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 7
- 210000000952 spleen Anatomy 0.000 claims description 7
- 239000012530 fluid Substances 0.000 claims description 6
- 230000003053 immunization Effects 0.000 claims description 6
- 206010003445 Ascites Diseases 0.000 claims description 5
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 claims description 5
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 claims description 5
- 238000004458 analytical method Methods 0.000 claims description 5
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 claims description 5
- 229940104230 thymidine Drugs 0.000 claims description 5
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 claims description 4
- 229960003896 aminopterin Drugs 0.000 claims description 4
- 230000001900 immune effect Effects 0.000 claims description 4
- 238000002955 isolation Methods 0.000 claims description 4
- 102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 claims description 3
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 claims description 3
- 230000002950 deficient Effects 0.000 claims description 3
- 241000283984 Rodentia Species 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 230000012010 growth Effects 0.000 claims description 2
- 239000012141 concentrate Substances 0.000 claims 1
- 239000000243 solution Substances 0.000 description 22
- 239000002609 medium Substances 0.000 description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- 238000003556 assay Methods 0.000 description 15
- 238000002835 absorbance Methods 0.000 description 14
- 239000003112 inhibitor Substances 0.000 description 13
- 239000006228 supernatant Substances 0.000 description 13
- -1 pentachlorophenol Chemical class 0.000 description 12
- 239000000758 substrate Substances 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 11
- 239000012528 membrane Substances 0.000 description 10
- 235000012431 wafers Nutrition 0.000 description 10
- 239000000463 material Substances 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 238000010367 cloning Methods 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 239000002023 wood Substances 0.000 description 6
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 239000003139 biocide Substances 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 229920003023 plastic Polymers 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000006957 competitive inhibition Effects 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- YCLSOMLVSHPPFV-UHFFFAOYSA-N 3-(2-carboxyethyldisulfanyl)propanoic acid Chemical compound OC(=O)CCSSCCC(O)=O YCLSOMLVSHPPFV-UHFFFAOYSA-N 0.000 description 2
- VURCJRMYKFUQSW-UHFFFAOYSA-N 3-[(3-chloro-3-oxopropyl)disulfanyl]propanoyl chloride Chemical compound ClC(=O)CCSSCCC(Cl)=O VURCJRMYKFUQSW-UHFFFAOYSA-N 0.000 description 2
- PORQOHRXAJJKGK-UHFFFAOYSA-N 4,5-dichloro-2-n-octyl-3(2H)-isothiazolone Chemical compound CCCCCCCCN1SC(Cl)=C(Cl)C1=O PORQOHRXAJJKGK-UHFFFAOYSA-N 0.000 description 2
- JNWGRCYCKMOLQW-UHFFFAOYSA-N 4-(5-chloro-3-oxo-1,2-thiazol-2-yl)butanoic acid Chemical compound OC(=O)CCCN1SC(Cl)=CC1=O JNWGRCYCKMOLQW-UHFFFAOYSA-N 0.000 description 2
- 108090001008 Avidin Proteins 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000001261 affinity purification Methods 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 108010030694 avidin-horseradish peroxidase complex Proteins 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 235000013861 fat-free Nutrition 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 125000001475 halogen functional group Chemical group 0.000 description 2
- 150000002431 hydrogen Chemical group 0.000 description 2
- 230000008105 immune reaction Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000010985 leather Substances 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000012038 nucleophile Substances 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- IZUPBVBPLAPZRR-UHFFFAOYSA-N pentachlorophenol Chemical compound OC1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1Cl IZUPBVBPLAPZRR-UHFFFAOYSA-N 0.000 description 2
- 150000002989 phenols Chemical class 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 2
- 229940080818 propionamide Drugs 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 150000003573 thiols Chemical class 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 description 1
- ANSCABGFLRQFHU-UHFFFAOYSA-N 3-(methylamino)-3-oxopropanoic acid Chemical compound CNC(=O)CC(O)=O ANSCABGFLRQFHU-UHFFFAOYSA-N 0.000 description 1
- 125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 description 1
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000008857 Ferritin Human genes 0.000 description 1
- 108050000784 Ferritin Proteins 0.000 description 1
- 238000008416 Ferritin Methods 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 241000893859 Matelea Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 235000005018 Pinus echinata Nutrition 0.000 description 1
- 241001236219 Pinus echinata Species 0.000 description 1
- 235000011334 Pinus elliottii Nutrition 0.000 description 1
- 235000017339 Pinus palustris Nutrition 0.000 description 1
- 235000008566 Pinus taeda Nutrition 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- UYCAGRPOUWSBIQ-WOYAITHZSA-N [(1s)-1-carboxy-4-(diaminomethylideneamino)butyl]azanium;(2s)-5-oxopyrrolidine-2-carboxylate Chemical compound OC(=O)[C@@H]1CCC(=O)N1.OC(=O)[C@@H](N)CCCN=C(N)N UYCAGRPOUWSBIQ-WOYAITHZSA-N 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 125000003710 aryl alkyl group Chemical class 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000012039 electrophile Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000009851 immunogenic response Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- MGIYRDNGCNKGJU-UHFFFAOYSA-N isothiazolinone Chemical compound O=C1C=CSN1 MGIYRDNGCNKGJU-UHFFFAOYSA-N 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000012913 medium supplement Substances 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- BEGLCMHJXHIJLR-UHFFFAOYSA-N methylisothiazolinone Chemical compound CN1SC=CC1=O BEGLCMHJXHIJLR-UHFFFAOYSA-N 0.000 description 1
- 238000007431 microscopic evaluation Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000010807 negative regulation of binding Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- JPMIIZHYYWMHDT-UHFFFAOYSA-N octhilinone Chemical compound CCCCCCCCN1SC=CC1=O JPMIIZHYYWMHDT-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000007142 ring opening reaction Methods 0.000 description 1
- 238000010079 rubber tapping Methods 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54353—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals with ligand attached to the carrier via a chemical coupling agent
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/815—Test for named compound or class of compounds
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/141111—Diverse hetero atoms in same or different rings [e.g., alkaloids, opiates, etc.]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US92776592A | 1992-09-28 | 1992-09-28 | |
| US07/927,765 | 1992-09-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2106693A1 true CA2106693A1 (en) | 1994-03-29 |
Family
ID=25455220
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002106693A Abandoned CA2106693A1 (en) | 1992-09-28 | 1993-09-22 | Immunoassay for isothiazolones |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US5554542A (es) |
| EP (1) | EP0592127B1 (es) |
| JP (1) | JPH07294522A (es) |
| KR (1) | KR940006604A (es) |
| CN (1) | CN1090929A (es) |
| AT (1) | ATE165009T1 (es) |
| AU (1) | AU675802B2 (es) |
| BR (1) | BR9303898A (es) |
| CA (1) | CA2106693A1 (es) |
| CZ (1) | CZ202693A3 (es) |
| DE (1) | DE69317976T2 (es) |
| DK (1) | DK0592127T3 (es) |
| ES (1) | ES2115022T3 (es) |
| HU (1) | HU214700B (es) |
| IL (1) | IL107055A0 (es) |
| MY (1) | MY109450A (es) |
| SG (1) | SG81877A1 (es) |
| TW (1) | TW258789B (es) |
| ZA (1) | ZA937028B (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6218181B1 (en) | 1998-03-18 | 2001-04-17 | The Salk Institute For Biological Studies | Retroviral packaging cell line |
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| NZ532151A (en) * | 2004-04-06 | 2007-09-28 | George William Mason John Brod | A method of quantitation of chemical preservatives within wood using enzyme linked immunosorbent assay technology combined with chromatographic analysis |
| WO2007001192A1 (en) * | 2005-06-28 | 2007-01-04 | Matthews, John, Brodie | Method of determining biocides within wood |
| DK1976877T4 (en) | 2005-11-30 | 2017-01-16 | Abbvie Inc | Monoclonal antibodies to amyloid beta protein and uses thereof |
| PL1954718T3 (pl) | 2005-11-30 | 2015-04-30 | Abbvie Inc | Przeciwciała skierowane przeciwko A globulomerowi, ich reszty wiążące antygeny, odpowiednie hybrydomy, kwasy nukleinowe, wektory, komórki gospodarze, sposoby wytwarzania tych przeciwciał, kompozycje zawierające te przeciwciała, zastosowania tych przeciwciał i sposoby stosowania tych przeciwciał |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| US20100311767A1 (en) | 2007-02-27 | 2010-12-09 | Abbott Gmbh & Co. Kg | Method for the treatment of amyloidoses |
| JP2013523182A (ja) | 2010-04-15 | 2013-06-17 | アボット・ラボラトリーズ | アミロイドベータ結合タンパク質 |
| EP2603524A1 (en) | 2010-08-14 | 2013-06-19 | AbbVie Inc. | Amyloid-beta binding proteins |
| US8912003B2 (en) | 2011-08-26 | 2014-12-16 | General Electric Company | Methods and devices for detecting isothiazolones |
| MX2021003295A (es) * | 2018-09-27 | 2021-07-16 | Pf Medicament | Enlazadores basados en sulfomaleimida y sus correspondientes conjugados. |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4456691A (en) * | 1983-02-28 | 1984-06-26 | Suad Stark | Antigen for PCB, antibody raised by same, and method of making same |
| US4652530A (en) * | 1985-07-15 | 1987-03-24 | Rohm And Haas Company | Monitoring method for isothiazolones in aqueous systems |
| US4865972A (en) * | 1986-08-22 | 1989-09-12 | Westinghouse Electric Corp. | Antibody-based bioassay for enzyme-inducing chemicals |
| IL83419A0 (en) * | 1986-09-15 | 1988-01-31 | Westinghouse Electric Corp | Antibodies reactive with chlorinated phenols,their preparation and their use |
| GB9017880D0 (en) * | 1990-08-15 | 1990-09-26 | Cambridge Innovation Brokers | Assay |
| US5094957A (en) * | 1990-12-10 | 1992-03-10 | Rohm And Haas Company | Quantitative method for determining concentration of 3-isothiazolone |
-
1993
- 1993-09-01 TW TW082107115A patent/TW258789B/zh active
- 1993-09-21 IL IL93107055A patent/IL107055A0/xx unknown
- 1993-09-22 AU AU47524/93A patent/AU675802B2/en not_active Ceased
- 1993-09-22 CA CA002106693A patent/CA2106693A1/en not_active Abandoned
- 1993-09-23 ES ES93307558T patent/ES2115022T3/es not_active Expired - Lifetime
- 1993-09-23 DE DE69317976T patent/DE69317976T2/de not_active Expired - Fee Related
- 1993-09-23 EP EP93307558A patent/EP0592127B1/en not_active Expired - Lifetime
- 1993-09-23 AT AT93307558T patent/ATE165009T1/de not_active IP Right Cessation
- 1993-09-23 DK DK93307558T patent/DK0592127T3/da active
- 1993-09-23 SG SG9604229A patent/SG81877A1/en unknown
- 1993-09-23 ZA ZA937028A patent/ZA937028B/xx unknown
- 1993-09-24 BR BR9303898A patent/BR9303898A/pt not_active Application Discontinuation
- 1993-09-25 MY MYPI93001955A patent/MY109450A/en unknown
- 1993-09-27 HU HU9302736A patent/HU214700B/hu not_active IP Right Cessation
- 1993-09-28 JP JP5264302A patent/JPH07294522A/ja active Pending
- 1993-09-28 US US08/128,451 patent/US5554542A/en not_active Expired - Fee Related
- 1993-09-28 CN CN93119841A patent/CN1090929A/zh active Pending
- 1993-09-28 KR KR1019930020143A patent/KR940006604A/ko not_active Application Discontinuation
- 1993-09-28 CZ CZ932026A patent/CZ202693A3/cs unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2115022T3 (es) | 1998-06-16 |
| DK0592127T3 (da) | 1999-01-04 |
| SG81877A1 (en) | 2001-07-24 |
| CZ202693A3 (en) | 1994-04-13 |
| AU4752493A (en) | 1994-04-14 |
| HU9302736D0 (en) | 1994-01-28 |
| CN1090929A (zh) | 1994-08-17 |
| TW258789B (es) | 1995-10-01 |
| US5554542A (en) | 1996-09-10 |
| AU675802B2 (en) | 1997-02-20 |
| ATE165009T1 (de) | 1998-05-15 |
| MY109450A (en) | 1997-01-31 |
| ZA937028B (en) | 1994-03-29 |
| JPH07294522A (ja) | 1995-11-10 |
| HUT67054A (en) | 1995-01-30 |
| EP0592127A1 (en) | 1994-04-13 |
| KR940006604A (ko) | 1994-04-25 |
| EP0592127B1 (en) | 1998-04-15 |
| DE69317976T2 (de) | 1998-11-12 |
| IL107055A0 (en) | 1993-12-28 |
| DE69317976D1 (de) | 1998-05-20 |
| BR9303898A (pt) | 1994-06-14 |
| HU214700B (hu) | 1998-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2106693A1 (en) | Immunoassay for isothiazolones | |
| Bignami et al. | Monoclonal antibody-based enzyme-linked immunoassays for the measurement of palytoxin in biological samples | |
| WO1994023018A1 (en) | Immunoassay for tetrachloroisophthalonitrile (chlorothalonil®), its derivatives and breakdown products | |
| CN109696548A (zh) | 一种检测氟虫腈的试剂盒及其制备方法和应用 | |
| CN109734745A (zh) | 一种杀螟硫磷的抗体的制备方法和应用 | |
| US6111079A (en) | Lead binding polypeptides and nucleotides coding therefore | |
| EP0260829A2 (en) | Antibodies reactive with chlorinated phenols and methods of preparing and using same | |
| JP3947283B2 (ja) | イプロジオン及びその代謝物のハプテン化合物、抗体及び測定方法 | |
| JP3188641B2 (ja) | ミクロブタニルのハプテン化合物、抗体及び測定方法 | |
| CN109608479A (zh) | 一种毒鼠强半抗原及单克隆抗体的制备方法与应用 | |
| Hokama et al. | Cross‐reactivity of ciguatoxin, okadaic acid, and polyethers with monoclonal antibodies | |
| EP0258006A2 (en) | Monoclonal antibodies reactive with chlorinated dibenzo-p-dioxins and method of preparing and using same | |
| CN113717255A (zh) | 一种多粘菌素b和粘菌素半抗原、人工抗原及其制备方法与应用 | |
| US5264556A (en) | Monoclonal antibodies for measuring okadaic acid | |
| JP3188642B2 (ja) | イマザリルのハプテン化合物、抗体及び測定方法 | |
| JPH08511164A (ja) | ブレキナールおよび類縁体の検出のためのイムノアッセイ試剤および方法 | |
| Mercader et al. | Production of high-affinity monoclonal antibodies for azinphos-methyl from a hapten containing only the aromatic moiety of the pesticide | |
| US20050208604A1 (en) | Assays for amphetamine and methamphetamine | |
| CA2045875C (en) | Monoclonal antibodies to mycosphaerella species | |
| JP3015306B2 (ja) | 酸アミド系化合物のハプテン化合物、抗体および測定方法 | |
| JP3686977B2 (ja) | 抗ウラシルモノクローナル抗体及びそれを産生するハイブリドーマ | |
| JP2993902B2 (ja) | トリフルミゾールのハプテン化合物、抗体及び測定方法 | |
| HU206772B (en) | Method and reagent set for immunological detecting atrazine and atrazine-derivatives and method for obtaining monoclonic antibiotics suitable to said detection | |
| Hokama et al. | Monoclonal antibodies (MonoAbs) to ciguatoxin and related polyethers | |
| EP0093776A1 (en) | Monoclonal antibodies against schistosoma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |